Bolt Biotherapeutics (NASDAQ:BOLT) Issues Quarterly Earnings Results, Misses Expectations By $1.46 EPS

Bolt Biotherapeutics (NASDAQ:BOLT) announced its earnings results on Tuesday. The company reported ($4.31) EPS for the quarter, missing the consensus estimate of ($2.85) by ($1.46), FiscalAI reports. Bolt Biotherapeutics had a negative net margin of 433.74% and a negative return on equity of 92.54%. The company had revenue of $0.03 million during the quarter, compared to the consensus estimate of $1.50 million.

Bolt Biotherapeutics Trading Up 1.7%

Shares of Bolt Biotherapeutics stock traded up $0.08 on Tuesday, reaching $4.78. 21,057 shares of the company’s stock were exchanged, compared to its average volume of 25,356. The company has a market capitalization of $9.18 million, a P/E ratio of -0.27 and a beta of 1.10. Bolt Biotherapeutics has a 52 week low of $3.91 and a 52 week high of $9.25. The firm’s 50-day moving average is $4.58 and its two-hundred day moving average is $5.14. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.59 and a current ratio of 3.59.

Wall Street Analysts Forecast Growth

BOLT has been the topic of several analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a report on Monday, April 20th. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Bolt Biotherapeutics in a report on Friday, March 13th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $34.00.

Hedge Funds Weigh In On Bolt Biotherapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC boosted its holdings in shares of Bolt Biotherapeutics by 92.2% during the 4th quarter. Renaissance Technologies LLC now owns 55,025 shares of the company’s stock worth $301,000 after buying an additional 26,400 shares in the last quarter. Susquehanna International Group LLP bought a new position in shares of Bolt Biotherapeutics during the 3rd quarter worth approximately $89,000. Shay Capital LLC bought a new position in shares of Bolt Biotherapeutics during the 3rd quarter worth approximately $85,000. Finally, Squarepoint Ops LLC boosted its holdings in shares of Bolt Biotherapeutics by 19.8% during the 3rd quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock worth $79,000 after buying an additional 2,448 shares in the last quarter. 86.70% of the stock is currently owned by institutional investors.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.